Vellucci, R.
Terenzi, R.
Kanis, J. A
Kress, H. G.
Mediati, R. D.
Reginster, J.-Y.
Rizzoli, R.
Brandi, M. L.
Article History
Received: 8 January 2018
Accepted: 6 March 2018
First Online: 4 April 2018
Compliance with ethical standards
:
: Renato Vellucci, Riccardo Terenzi, Rocco Domenico Mediati, Jean-Yves Reginster, René Rizzoli and Maria Luisa Brandi declare that they have no conflict of interest. John A. Kanis reports grants from Amgen, grants from Lilly, grants from Radius Health, other from Meda, grants and other from UCB, outside the submitted work; and John A. Kanis is a member of the National Osteoporosis Guideline Group (NOGG) and the principal architect of FRAX but derives no financial benefit. Hans G. Kress received speaker’s and/or consultancy honoraria from the following pharmaceutical companies: Abbott, Astellas, bene-Arzneimittel, Berlin-Chemie/Menarini, Bionorica SE, Boehringer Ingelheim, Boston Scientific, CSC Pharmaceuticals, Grünenthal GmbH, IBSA, Linde Group, Medtronic, Mundipharma International, Nevro, Pfizer, Teva ratiopharm and Trigal Pharma.